Interim Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States.

Nevena Vicic¹, Alina Bogdanov², Heather Hensler³, Taylor Ryan², Ni Zeng², Ekkehard Beck³, Emily Patry³, Machaon Bonafede², Andre B Araujo³, Amanda Wilson³

¹Moderna, Inc., Cambridge, MA, USA. Nevena.Vicic@modernatx.com.

²Real World Evidence, Veradigm, Chicago, IL, USA.

³Moderna, Inc., Cambridge, MA, USA.

PubMed DOI

Abstract

INTRODUCTION: The 2025-2026 COVID-19 vaccine season introduced updated formulations targeting the LP.8.1 lineage. This interim analysis assessed absolute vaccine effectiveness (aVE) of mRNA-1283 and BNT162b2 on COVID-19 outcomes in adults aged ≥ 65 years. METHODS: This retrospective study used linked electronic health record and administrative claims data through January 31, 2026. Adults ≥ 65 yea…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.